NCT04231435View on ClinicalTrials.gov

Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 18, 2019

Primary Completion Date

February 19, 2020

Study Completion Date

February 21, 2020

Conditions
Healthy Volunteers
Interventions
DRUG

Fedratinib

Oral

DRUG

Digoxin

Oral

DRUG

Rosuvastatin

Oral

DRUG

Metformin

Oral

Trial Locations (1)

78744

PPD Phase 1 Clinic, Austin

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
collaborator

Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

INDUSTRY

lead

Celgene

INDUSTRY